<DOC>
	<DOCNO>NCT01067443</DOCNO>
	<brief_summary>This study ass shorter combination SSG plus single dose AmBisome® , Miltefosine plus single dose AmBisome® Miltefosine alone effective treat visceral leishmaniasis Eastern Africa .</brief_summary>
	<brief_title>Clinical Trial Assess Safety Efficacy Sodium Stibogluconate ( SSG ) AmBisome® Combination , Miltefosine AmBisome® Miltefosine Alone Treatment Visceral Leishmaniasis Eastern Africa</brief_title>
	<detailed_description>The current study intend look potential feasible short course combination therapy well evaluate ( possibly register ) miltefosine conventional dose VL Sudan Kenya .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>Patients clinical sign symptom VL diagnosis confirm visualization parasite tissue sample ( lymph node , bone marrow spleen relevant ) microscopy . Patients age 7 ( allow blood sample ) 60 year ( inclusive ) able comply protocol . Patients write informed consent sign patient ( age 18 year ) parent ( ) legal guardian patient 18 year age . HIV negative status Patients receive antileishmanial drug last 6 months/ relapse case . Patients negative lymph node/bone marrow ( spleen ) smear . Patients severe protein caloric malnutrition ( Kwashiorkor marasmus ; Adults : BMI &lt; /= 15 , Children W/H &lt; 70 , presence oedema ) Patients previous history hypersensitivity reaction SSG Amphotericin B . Patients suffer concomitant severe infection TB serious underlie disease ( cardiac , renal , hepatic ) would preclude evaluation patient 's response study medication . Patients suffer condition associate splenomegaly schistosomiasis . Patients previous history cardiac arrhythmia abnormal ECG Patients female child bearing age ( female achieve menarche ) / pregnant lactating . Patients haemoglobin &lt; 5gm/dl . Patients WBC &lt; 1 x 10³/mm³ . Patients platelets &lt; 40,000/mm³ . Patients abnormal liver function ( ALT AST ) test three time normal range . Patients serum creatinine outside normal range age gender . Major surgical intervention within 2 week prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Randomised clinical trial</keyword>
	<keyword>Visceral Leishmaniasis</keyword>
</DOC>